A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.

Autor: Roche JA; Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA., Roche R; College of Health and Human Services, Eastern Michigan University, Ypsilanti, MI, USA.
Jazyk: angličtina
Zdroj: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2020 Jun; Vol. 34 (6), pp. 7265-7269. Date of Electronic Publication: 2020 May 02.
DOI: 10.1096/fj.202000967
Abstrakt: As of April 20, 2020, over time, the COVID-19 pandemic has resulted in 157 970 deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%. With the pandemic rapidly spreading, and health delivery systems being overwhelmed, it is imperative that safe and effective pharmacotherapeutic strategies are rapidly explored to improve survival. In this paper, we use established and emerging evidence to propose a testable hypothesis that, a vicious positive feedback loop of des-Arg(9)-bradykinin- and bradykinin-mediated inflammation → injury → inflammation, likely precipitates life threatening respiratory complications in COVID-19. Through our hypothesis, we make the prediction that the FDA-approved molecule, icatibant, might be able to interrupt this feedback loop and, thereby, improve the clinical outcomes. This hypothesis could lead to basic, translational, and clinical studies aimed at reducing COVID-19 morbidity and mortality.
(© 2020 Federation of American Societies for Experimental Biology.)
Databáze: MEDLINE
Externí odkaz: